Lifeboat Foundation

The Microsoft-Mistral agreement draws the scrutiny of the European Commission.

Microsoft has inked a multi-year partnership with French startup Mistral AI to make its artificial intelligence (AI) models, like ‘Le Chat,’ available through the Azure cloud computing platform.

Essentially, Microsoft’s investment will be used to purchase equity in Mistral. The valuation of Mistral AI remains the same even after Microsoft’s investment.

Continue reading “Mistral AI: Microsoft invests $16M in OpenAI French doppelgänger” »

This little fish emits noises as loud as a gunshot, topping 140 decibels.

One of the world’s smallest fish lives in Myanmar’s streams, and experts have been surprised by its high sound.

Samsung doubles down in HBM race with largest memory.

Samsung has unveiled a new memory chip, which it claims is the ‘highest-capacity to date’ for artificial intelligence (AI) applications.

Discover the groundbreaking capabilities of Xiaomi’s CyberDog 2, a bio-inspired quadruped robot leaping forward in robotics!

Wonderful work truly breakthrough for different types of compounds for chemistry. Year 2021.

V-SYNTHES, a scalable and computationally cost-effective synthon-based approach to compound screening, identified compounds with a high affinity for CB2 and CB1 in a hierarchical structure-based screen of more than 11 billion compounds.

From the spirals of shells to the layout of cells, a new class of shapes redefines nature’s complexity.

One of the immune system’s primary roles is to detect and kill cells that have acquired cancerous mutations. However, some early-stage cancer cells manage to evade this surveillance and develop into more advanced tumors.

A new study from MIT and Dana-Farber Cancer Institute has identified one strategy that helps these precancerous cells avoid immune detection. The researchers found that early in colon cancer development, cells that turn on a gene called SOX17 can become essentially invisible to the immune system.

If scientists could find a way to block SOX17 function or the pathway that it activates, this may offer a new way to treat early-stage cancers before they grow into larger tumors, the researchers say.

Most cancers are thought to evade the immune system. These cancers don’t carry very many mutations, and they aren’t infiltrated by cancer-fighting immune cells. Scientists call these cancers immunologically “cold.”

Now new research suggests such cancers aren’t as “cold” as once thought. Researchers from the La Jolla Institute for Immunology (LJI), UC San Diego Moores Cancer Center, and UC San Diego, have found that patients with “cold” tumors actually do make cancer-fighting T cells.

This discovery opens the door to developing vaccines or therapies to increase T cell numbers and treat many more types of cancer than currently thought possible.

Researchers at the University of Colorado Anschutz Medical Campus studying interactions between nerves and tumor microenvironments have found that commonly used drugs like botox may stop or slow the progression of certain head and neck cancers.

The study, published online today in the journal Med, examined how nerves within the tumor environment impact the immune system and cancer growth.

“We have long known that the intensity of nerve interactions within the tumor microenvironment are associated with worse outcomes in head and neck squamous cell carcinoma,” said the study’s lead author Laurel Darragh, an MD/Ph. D. student focused on radiation oncology at the University of Colorado School of Medicine. “This prompted us to investigate how these nerve interactions impact the adaptive immune system and tumor growth.”